Hepatitis/MASH

Drugs that target the signal-peptide peptidase enzyme may halt HCV development.

Baby boomer generation are five times more likely to be diagnosed with hepatitis C virus.

Large pharmaceutical companies who use this financial model could affect access to life-saving drugs.

Debate continues surrounding cost versus cure in hepatitis C treatment.

Top news of the day from across the health care landscape.

Zepatier is already approved in the United States and Canada for treatment of hepatitis C.

CDC raises concerns about mother-to-child transmission of hepatitis C virus.

Jennifer Andres, PharmD, BCPS, clinical assistant professor of pharmacy practice at Temple University School of Pharmacy discusses the sorts of services pharmacists can provide for hepatitis C patients.

Jennifer Andres, PharmD, BCPS, clinical assistant professor of pharmacy practice at Temple University Schools of pharmacy describes how hepatitis C care in the pharmacy differs from care provided in other settings.

Veikira XR is a once-daily medication that treats hepatitis C genotype 1.

Veikira XR is a once-daily medication that treats hepatitis C genotype 1.

The United States was found to have higher prescription and surgery costs compared with other countries.

Specialty pharmacists play an important role in making evidence-based recommendations for the treatment of hepatitis C virus.

Is the cost of specialty drugs worth the price in small patient populations?

Patients treated with HCV drugs prior to transplant found to have higher overall post-transplant care costs.

Restricted access to antiviral HCV treatments only reduces spending in the short-term.

Positive relationship found between the pricing of HCV drug regimens with the rate of sustained viral response.

Restrictions begin to lift for high cost hepatitis C drugs.

Restricted access to antiviral HCV treatments only reduces spending in the short-term.

Four major hepatitis genotypes kill more people than HIV, malaria, and tuberculosis.

Top news of the day from across the health care landscape.

Threat of legal action prompts several states to allow greater access to curative HCV drugs.

Top news of the day from across the health care landscape.

Approximately 58% of patients with nonalcoholic steatohepatitis treated with pioglitazone showed reduced disease activity.

Nonalcoholic fatty liver disease is the buildup of extra fat in the liver that isn't caused by alcohol abuse.